Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19Zara Izadi, Philippe Goupille, Erica J. Brenner et al.|JAMA Network Open|2021Cited by 117
Sociodemographic and clinical factors associated with poor COVID-19 outcomes in patients with rheumatic diseases: data from the SAR-COVID RegistryC. A. Isnardi, César Graf, Karen Roberts et al.|Clinical Rheumatology|2022Cited by 21
A longitudinal multiethnic study of biomarkers in systemic lupus erythematosus: Launching the GLADEL 2.0 Study GroupJosé A. Gómez‐Puerta, Ignacio García‐De La Torre, Guillermo Pons‐Estel et al.|Lupus|2021Cited by 14
Temporal trends in COVID-19 outcomes in people with rheumatic diseases in Ireland: data from the COVID-19 Global Rheumatology Alliance registryRichard Conway, María Alejandra Medina, Elena Nikiphorou et al.|Lara D. Veeken|2022Cited by 7
Thrombocytopenia and autoimmune hemolytic anemia in antiphospholipid antibody-positive patients: Descriptive analysis of the AntiPhospholipid syndrome alliance for clinical trials and InternatiOnal networking (APS ACTION) clinical database and repository (“Registry”)Zeynep Belce Erton, Doruk Erkan, Maria Efthymiou et al.|Lupus|2025Cited by 2